The global mycoplasma testing in the clinical market is focused on ensuring the purity and safety of biomedical research and applications, given the significant threat posed by mycoplasma contamination to cell cultures, vaccines, and biopharmaceuticals. A March 2020 report on "Mycoplasma genitalium Urethritis" highlights MG as a major cause of male urethritis, with a 28.7% infection rate in a study of 914 participants. Additionally, a February 2019 study found Mycoplasma in the rectum and anal canal of Crohn's disease patients, suggesting its role in gastrointestinal infections.
Data Bridge Market Research analyses that the Global Mycoplasma Testing in the Clinical Market, which was USD 295.06 million in 2022, is expected to reach USD 526.23 million by 2030, at a CAGR of 7.5% during the forecast period 2023 to 2030.
"Increasing research and development investments drive the market growth"
The increase of research and development investments in mycoplasma testing tools is driven by the imperative for highly efficient testing methodologies. As research costs rise, key companies recognize the critical need for robust mycoplasma testing to ensure the integrity and safety of their biomedical products. Increased research and development investments signify a commitment to advancing testing technologies, fostering innovation, and meeting stringent regulatory requirements. This proactive approach enhances the reliability of test results and reflects a strategic investment in maintaining the quality and purity of cell cultures, vaccines, and biopharmaceuticals, safeguarding the integrity of biomedical research and applications.
What restraints the growth of the global mycoplasma testing in clinical market?
" High cost of instruments hamper the market growth"
The mycoplasma testing in clinical market faces a hindrance in the form of the high cost of instruments, anticipated to impede growth throughout the forecast period. This financial barrier challenges laboratories, research institutions, and biopharmaceutical companies, limiting their capacity to invest in sophisticated testing equipment. The elevated costs associated with acquiring and maintaining these instruments hinder broader adoption, potentially restricting access to advanced mycoplasma testing technologies and compromising the progress and expansion of the market.
Segmentation: Global Mycoplasma Testing In Clinical Market
The global mycoplasma testing in clinical market is segmented on the basis of products, technique, application, disease area, and end user.
- On the basis of products, the global mycoplasma testing in clinical market is segmented into kits and reagents, instruments and services
- On the basis of technique, the gobal mycoplasma testing in clinical market is segmented into microbial culture techniques/direct assay, polymerase chain reaction, ELISA, DNA staining/ indirect assay, enzymatic methods
- On the basis of application, the gobal mycoplasma testing in clinical market is segmented into cell line testing and virus testing
- On the basis of disease area, the global mycoplasma testing in clinical market is segmented into respiratory, urogenital, gastrointestinal, cardiovascular, musculoskeletal, and others
- On the basis of end user, the global mycoplasma testing in clinical market is segmented into hospitals and diagnostics laboratories
Regional Insights: North America dominates the Global Mycoplasma Testing In Clinical Market
North America dominates the global mycoplasma testing in the clinical market, driven by the recurring acquisition of consumables for mycoplasma detection in cell culture. The kits and reagents segment is poised for rapid growth, reflecting the increasing demand for these essential components. This trend underscores North America's pivotal role in the market's expansion, emphasizing the region's consistent investment in mycoplasma testing consumables, particularly within the kits and reagents category.
Asia-Pacific is expected to dominate the global mycoplasma testing in clinical market from 2023 to 2030, experiencing the highest growth rate. This projection is fueled by a surge in demand for effective testing within the region, particularly in the kits and reagents segment. The increased emphasis on reliable mycoplasma testing in Asia-Pacific reflects the growing significance of stringent quality standards in biomedical research and applications, driving the market's expansion in the forecast period.
Recent Developments: Global Mycoplasma Testing In Clinical Market
- In 2020, Liofilchem S.r.l launched the AF Genital System, VTM, Lockable contact plates, enhancing microbial testing. This upgrade contributed to increased revenue for the company
- In 2020, BioMérieux SA launched the biofire mycoplasma test for biopharmaceutical products, expanding its product usage in the biotherapeutics market
To know more about the study, visit https://www.databridgemarketresearch.com/de/reports/global-mycoplasma-testing-in-clinical-market
The Prominent Key Players Operating in the Global Mycoplasma Testing In Clinical Market Include:
- AB ANALITICA s.r.l. (Italy)
- BIOMÉRIEUX (France)
- ELITechGroup (France)
- Liofilchem S.r.l. (Italy)
- Agilent Technologies, Inc. (U.S.)
- PromoCell GmbH (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- OSANG Healthcare (South Korea)
- Sacace Biotechnologies Srl (Italy)
- Lonza (Switzerland)
- Merck KGaA (Germany)
- Seegene Inc. (South Korea)
- Clongen Laboratories, LLC (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Charles River Laboratories (U.S.)
- Bionique Testing Laboratories LLC (U.S.)
- ZEAKON Diagnostics (India)
Above are the key players covered in the report, to know about more and exhaustive list of global mycoplasma testing in clinical market companies, contact: https://www.databridgemarketresearch.com/de/contact
Research Methodology: Global Mycoplasma Testing In Clinical Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
